SAN DIEGO, Jan. 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), () today announced that its research and development team at its NexMed, USA, Inc. ("NexMed, USA") ...

SAN DIEGO, June 1, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), today announced that it has produced a series of online videos on the Company's NexACT® drug ...

SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT ® drug delivery technology ...

SAN DIEGO--(BUSINESS WIRE)-- NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, today announced data from a pre-clinical study examining the ...

SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences (“Apricus Bio,” formerly NexMed, Inc.) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT ® ...

What it does: Develops new formulations of government-approved drugs using its patented NexACT molecules, which loosen so-called tight junctions that bind skin cells to each other, creating space for ...

Robbinsville, NJ, May 23, 2005--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal treatments based on its proprietary NexACT® drug delivery technology, today announced the preliminary ...

Deck: A potential blockbuster product isn”t enough, if you”ve run out of money. Story: A small Robbinsville drug company just received a jolt every bit as exciting as the effect its lead product has ...

SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT ® technology, today announced the appointments of Jack A. Reynolds, Ph.D and ...

Pursuant to the MOU, PII will promote the NexACT technology to its clients and may independently identify new product development opportunities for this collaboration with NexMed. PII will be ...